Loading…
Loading…
UroGen Pharma is shifting NMIBC treatment from surgery to office-based chemoablative therapy with ZUSDURI, driving a differentiated investment thesis. ZUSDURI revenue surged 109% sequentially to $29.2M in Q1 2026; repeat prescribers and workflow integration signal durable adoption and positive operating leverage. URGN's premium valuation is justified by a $5B+ TAM, durable clinical data, patent protection to 2044, and a de-risked pipeline including UGN-103.
PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
According to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds. The sale represented 8% of the insider's direct equity holdings in the company, as reported in the Form 4.
FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation PRINCETON, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
10,000 shares were sold for a transaction value of ~$350,000 at a weighted average price of around $35.01 per share on June 22, 2026. The sale represented 7.15% of Mark Schoenberg's direct holdings, reducing his position from 139,763 to 129,763 shares of common stock.
5,222 shares were sold on June 8, 2026 for a transaction value of approximately $143,000 at a weighted average price around $27.30 per share. The transaction represented 3.60% of Mark Schoenberg's direct holdings, reducing his position from 144,985 to 139,763 shares.
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for URGN and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.